687 related articles for article (PubMed ID: 18596007)
1. Lipid screening and cardiovascular health in childhood.
Daniels SR; Greer FR;
Pediatrics; 2008 Jul; 122(1):198-208. PubMed ID: 18596007
[TBL] [Abstract][Full Text] [Related]
2. The use of lipid-lowering drug therapy in children and adolescents.
Avis HJ; Vissers MN; Wijburg FA; Kastelein JJ; Hutten BA
Curr Opin Investig Drugs; 2009 Mar; 10(3):224-31. PubMed ID: 19333879
[TBL] [Abstract][Full Text] [Related]
3. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
[TBL] [Abstract][Full Text] [Related]
4. On the road to better dyslipidemia outcomes.
Hughes S
Nurse Pract; 2009 Feb; 34(2):14-21; quiz 22. PubMed ID: 19155874
[No Abstract] [Full Text] [Related]
5. [Therapy of dyslipidemia in post-infarction: state of the art].
Borgia MC; Nardi M; Da Ros S; Castellano V
Clin Ter; 2007; 158(6):523-32. PubMed ID: 18265719
[TBL] [Abstract][Full Text] [Related]
6. A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome.
Davidson M
Am J Cardiol; 2008 Dec; 102(12A):19L-27L. PubMed ID: 19084086
[TBL] [Abstract][Full Text] [Related]
7. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
Jones PH
Am J Cardiol; 2008 Dec; 102(12A):41L-47L. PubMed ID: 19084089
[TBL] [Abstract][Full Text] [Related]
8. Management of dyslipidemia in children and adolescents with systemic lupus erythematosus.
Ardoin SP; Sandborg C; Schanberg LE
Lupus; 2007; 16(8):618-26. PubMed ID: 17711898
[TBL] [Abstract][Full Text] [Related]
9. Colesevelam hydrochloride in the management of dyslipidemia.
Armani A; Toth PP
Expert Rev Cardiovasc Ther; 2006 May; 4(3):283-91. PubMed ID: 16716090
[TBL] [Abstract][Full Text] [Related]
10. Lipid management in the geriatric patient.
Nair AP; Darrow B
Endocrinol Metab Clin North Am; 2009 Mar; 38(1):185-206. PubMed ID: 19217519
[TBL] [Abstract][Full Text] [Related]
11. Managing dyslipidemia in chronic kidney disease.
Harper CR; Jacobson TA
J Am Coll Cardiol; 2008 Jun; 51(25):2375-84. PubMed ID: 18565393
[TBL] [Abstract][Full Text] [Related]
12. Lipid management in children.
Zappalla FR; Gidding SS
Endocrinol Metab Clin North Am; 2009 Mar; 38(1):171-83. PubMed ID: 19217518
[TBL] [Abstract][Full Text] [Related]
13. Obesity and cardiometabolic syndrome in children.
Velasquez-Mieyer P; Neira CP; Nieto R; Cowan PA
Ther Adv Cardiovasc Dis; 2007 Oct; 1(1):61-81. PubMed ID: 19124396
[TBL] [Abstract][Full Text] [Related]
14. [Diabetic dyslipoproteinemia: beyond LDL].
Merkel M
Dtsch Med Wochenschr; 2009 May; 134(20):1067-73. PubMed ID: 19421932
[TBL] [Abstract][Full Text] [Related]
15. Treatment of the dyslipidemia of insulin resistance.
Smith DA
Med Clin North Am; 2007 Nov; 91(6):1185-210, x. PubMed ID: 17964916
[TBL] [Abstract][Full Text] [Related]
16. Solvay addresses unmet needs in the management of hypertensive patients with cardiometabolic and lipid disorders.
Cardiovasc J Afr; 2009; 20(1):73-4. PubMed ID: 19287821
[No Abstract] [Full Text] [Related]
17. Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk.
Brown BG; Zhao XQ
Am J Cardiol; 2008 Apr; 101(8A):58B-62B. PubMed ID: 18375243
[TBL] [Abstract][Full Text] [Related]
18. Treating dyslipidaemia in the setting of diabetes mellitus and cardiovascular disease: another focus.
Tahrani AA
Int J Clin Pract; 2006 Nov; 60(11):1515; author reply 1515-6. PubMed ID: 17073848
[No Abstract] [Full Text] [Related]
19. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts).
Graham I; Atar D; Borch-Johnsen K; Boysen G; Burell G; Cifkova R; Dallongeville J; De Backer G; Ebrahim S; Gjelsvik B; Herrmann-Lingen C; Hoes A; Humphries S; Knapton M; Perk J; Priori SG; Pyorala K; Reiner Z; Ruilope L; Sans-Menendez S; Op Reimer WS; Weissberg P; Wood D; Yarnell J; Zamorano JL; Walma E; Fitzgerald T; Cooney MT; Dudina A; Vahanian A; Camm J; De Caterina R; Dean V; Dickstein K; Funck-Brentano C; Filippatos G; Hellemans I; Kristensen SD; McGregor K; Sechtem U; Silber S; Tendera M; Widimsky P; Zamorano JL; Altiner A; Bonora E; Durrington PN; Fagard R; Giampaoli S; Hemingway H; Hakansson J; Kjeldsen SE; Larsen ML; Mancia G; Manolis AJ; Orth-Gomer K; Pedersen T; Rayner M; Ryden L; Sammut M; Schneiderman N; Stalenhoef AF; Tokgözoglu L; Wiklund O; Zampelas A; ; ; ; ; ; ; ; ; ;
Eur J Cardiovasc Prev Rehabil; 2007 Sep; 14 Suppl 2():E1-40. PubMed ID: 17726406
[No Abstract] [Full Text] [Related]
20. Drug treatment of lipid disorders.
Knopp RH
N Engl J Med; 1999 Aug; 341(7):498-511. PubMed ID: 10441607
[No Abstract] [Full Text] [Related]
[Next] [New Search]
